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A B S T R A C T
The applications of modern artiﬁcial intelligence (AI) algorithms within the ﬁeld of aging research oﬀer tre-
mendous opportunities. Aging is an almost universal unifying feature possessed by all living organisms, tissues,
and cells. Modern deep learning techniques used to develop age predictors oﬀer new possibilities for formerly
incompatible dynamic and static data types. AI biomarkers of aging enable a holistic view of biological processes
and allow for novel methods for building causal models—extracting the most important features and identifying
biological targets and mechanisms. Recent developments in generative adversarial networks (GANs) and re-
inforcement learning (RL) permit the generation of diverse synthetic molecular and patient data, identiﬁcation
of novel biological targets, and generation of novel molecular compounds with desired properties and ger-
oprotectors. These novel techniques can be combined into a uniﬁed, seamless end-to-end biomarker develop-
ment, target identiﬁcation, drug discovery and real world evidence pipeline that may help accelerate and im-
prove pharmaceutical research and development practices. Modern AI is therefore expected to contribute to the
credibility and prominence of longevity biotechnology in the healthcare and pharmaceutical industry, and to the
convergence of countless areas of research.
1. Introduction
Aging can be deﬁned as a gradual, multifactorial, time-dependent
process leading to the loss of function, biological and physical damage,
and the onset of multiple age-related diseases. Aging progressively af-
fects most regulatory mechanisms due to the hierarchical organization
of living systems. The human organism is a multi-level, complex system
comprised of billions of independent cells that form diﬀerent types of
tissues. These tissues are the main blocks used to assemble organs, and
these organs are organized in diﬀerent systems including the lymphatic,
respiratory, digestive, urinary, or reproductive systems to achieve
speciﬁc tasks. Aging can be inﬂuenced by the complex interplay be-
tween environmental, mechanistic, biochemical and evolutionary con-
straints. Therefore, dysfunctions aﬀecting only a few biological pro-
cesses within the cells of one or several organs can propagate to all parts
of the body. This explains why aging cannot be fully understood or
controlled when monitoring only a restricted number of physiological
processes. Taken together, aging appears to be the long-term result of
the disruption of diﬀerent dynamical equilibriums established between
antagonistic processes, rather than the result of a sudden appearance of
isolated molecular processes or components with intrinsic negative ef-
fects. The systemic and multifactorial nature of aging explains why
understanding its biology and mechanisms are so complex and why, as
a consequence, aging research is continuously in need of multi-
disciplinary and global approaches. Novel experimental techniques
have allowed the generation and accumulation of a huge amount of
aging-related data, including genomic (Gleeson et al., 2017) (Yi et al.,
2013) (Yi et al., 2013) (Bennett et al., 2016), transcriptomic (Artemov
et al., 2015) (Bolotin et al., 2017), microRNA (Zabolotneva et al.,
2013), proteomic (Di Meo et al., 2016), antigen (Ionov, 2010), me-
thylation (Yin et al., 2017), imaging (Lee et al., 2017a,b) (Niklinski
et al., 2017), metagenomic (Alexander et al., 2017), mitochondrial
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(Sotgia and Lisanti, 2017), metabolic (Nielsen, 2017) and physiological
(Pretorius and Bester, 2016). These data provide an unprecedented
detailed overview of the aging process. However, the analysis and
practical use of the information contained within this huge amount of
data also requires adapted computational approaches such as machine
learning (ML) and, more recently, the development of deep learning
(DL) techniques which are the cornerstones of modern artiﬁcial in-
telligence (AI) technologies. From this point of view, recent AI advances
have had a major impact within the ﬁeld of aging research (Moskalev
et al., 2017). The attractive feature of AI is its ability to identify re-
levant patterns within complex, nonlinear data, without the need for
any a priori mechanistic understanding of the biological processes. AI
unveils the mechanistic relationships taking place within the body.
Today, DL and AI algorithms have been successfully developed and
applied in many pharmaceutical areas (Mamoshina et al., 2016;
Gawehn et al., 2015; Lenselink et al., 2017; Chen et al., 2018) with
applications as wide-ranging as prediction of organic chemistry reac-
tions (Wei et al., 2016), identiﬁcation of aging biomarkers
(Zhavoronkov et al., 2016), optimization of chemical synthesis (Segler
et al., 2018), prediction of pharmacological properties of drugs (Aliper
et al., 2016), analysis of relationships between certain lifestyle choices
like smoking and accelerated aging (Mamoshina et al., 2018c), in-
vestigation of protein secondary structure (Spencer et al., 2015),
modeling features of RNA-binding protein targets (Zhang et al., 2016),
analysis of drug-induced hepatotoxicity (Xu et al., 2015), or the study of
long non-coding RNAs (Fan and Zhang, 2015).
As emphasized by Deep Knowledge Analytics (www.dkv.global/
analytics) in its recent industry analytical report entitled ‘AI for Drug
Discovery, Biomarker Development and Advanced R&D 2018,’ AI is
expected to make a major impact on healthcare. It can be used for the
development of eﬀective personalized medicine based on the inter-
pretation of large medical databases gathered over the years by com-
panies and healthcare providers. There are currently several companies
applying AI technologies within the ﬁeld of aging research. Bioage is a
company using ML and genomic data for the development of bio-
markers of aging and drug discovery for aging and age-related disease.
Insilico Medicine is developing DL-based algorithms and deploying an
integrated AI pipeline for aging research, biomarker development, and
drug discovery in one end-to-end learning pipeline. The goal of the
company is to ﬁnd novel solutions for aging and age-related diseases
using advances in genomics, AI, and big data analysis. Atomwise is
using AI for aging research with a drug discovery pipeline targeting
age-related diseases that still lack eﬀective treatments, like Alzheimer’s
disease. These examples illustrate that AI technologies can be applied at
diﬀerent levels, with the goal of facilitating the development of new
pharmaceuticals quicker, cheaper, and more eﬀectively (Fleming,
2018). AI can be applied for accelerating the identiﬁcation of bio-
markers of age, for the identiﬁcation of new targets and geroprotectors,
for accelerating and optimizing the development of new compounds
with speciﬁc desired properties, to improve patient prognosis by re-
ducing error rate, for helping to select the most appropriate treatment
by predicting treatment outcome (Trtica-Majnaric et al., 2010), and for
predicting the chance of drug success during clinical trials or clinical
trials outcomes. For a broad overview of the use of AI in biomedicine,
we refer the reader to these current reviews (Rifaioglu et al., 2018;
Ching et al., 2018; Tsigelny, 2018; Fabris et al., 2017).
The aim of this review is to provide a technical overview of the
advances and opportunities oﬀered by AI for aging biomarkers devel-
opment and anti-aging drugs discovery. This work emphasizes that
despite their speciﬁc technical requirements, the computational
methods used for these tasks can be integrated within a single workﬂow
to optimize several steps of aging research—from the identiﬁcation of
aging signatures to target identiﬁcation and ad hoc molecule genera-
tion. Currently, biomarker development is an intensive area of research
in geroscience, as it lays the foundation for eﬃcient preclinical and
clinical evaluation of potential health span-extending interventions. We
describe how deep learned aging clocks are used to identify aging
biomarkers and other targets of interest. The emergence of AI-based
methods for small molecule drug discovery is a major change in the
standard drug discovery pipeline. For decades, computational methods
have been used for accelerating the identiﬁcation of potential leads
during the early stages of the drug discovery process. However, with its
ability to generate molecules with speciﬁc properties, AI based mole-
cular generators provide new, promising opportunities. At this time, the
main algorithms designed to that end are described, and the advantages
and current challenges of these approaches are summarized. One of the
major challenges for the use of AI technology is to obtain more reliable
predictions. This relies strongly on the ability to extract the most re-
levant features. This paper examines the current strategies used in aging
research to extract more biologically relevant features and make AI-
based models more easily interpretable. To conclude, a short discussion
addresses a challenge speciﬁc to the development of increasing use of
AI within healthcare—privacy protection regulatory issues, which be-
came a major concern with the increasing amount of personal data
being stored, used, or even shared by AI-powered healthcare applica-
tions.
2. Advances in artiﬁcial intelligence
2.1. Machine learning
Machine learning (ML) refers to algorithms that can learn from and
make predictions on data by building a model from sample inputs. ML
is commonly employed for computing tasks where designing and pro-
gramming explicit algorithms with good performance is diﬃcult or
infeasible. Today, most commonly used traditional ML methods include
k-nearest neighbors (kNN) (Altman, 1992; Kramer, 2013), logistic re-
gression (LR) (Walker and Duncan, 1967), support vector machines
(SVM), also called support vector networks (Cortes and Vapnik, 1995),
gradient boosting machines (GBM) (Mason et al., 1999; Friedman,
2001; Ayyadevara and Kishore Ayyadevara, 2018), and random forest
(RF) (Ho, 1995; Breiman, 2001; Fratello and Tagliaferri, 2018). The
performance of these methods can vary depending on the type of task
(regression or classiﬁcation), types, and amount of data to handle.
2.2. Deep learning
Deep structured learning, also called deep learning (DL) or hier-
archical learning, refers to a class of ML techniques that exploit many
layers of non-linear computational units to model complex relationships
among data. These architectures, composed of multiple layers, are
commonly called deep neural networks (DNNs), or sometimes stacked
neural networks. The diﬀerence between the initial single-hidden-layer
artiﬁcial neural networks (ANNs) and DNNs is the depth; that is, the
number of layers of nodes through which data is processed. Usually,
more than three layers (including input and output) qualify as "deep"
learning. Thus, "deep" is a technical term that means more than one
hidden layer. As other standard neural network architectures, DNNs are
eﬃcient universal approximators. But they have additional character-
istics as they are based on the learning of multiple levels of features or
representations of the data. They use a cascade of many layers of
nonlinear processing units for feature extraction. Each successive layer
uses the output from the previous layer as input. Higher level features
are derived from lower level features to form a hierarchical re-
presentation. This hierarchy of features is called a deep architecture.
These methods are capable of learning multiple levels of representa-
tions that correspond to diﬀerent levels of abstraction. These levels
form a hierarchy of concepts. Among the diﬀerent architectures pro-
posed so far, recurrent neural networks, generative adversarial net-
works, and transfer learning techniques are gaining popularity within
aging research and are often considered for various applications in
healthcare. As a consequence of the rise of DL, traditional ML methods
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are now commonly used as baseline models to assess the performance
of more recent DNN-based models.
2.3. Reinforcement learning
Reinforcement learning (RL) refers to goal-oriented algorithms,
which learn how to attain a complex objective or maximize along a
particular dimension over many steps (Arulkumaran et al., 2017;
Kulkarni, 2017). The key feature of RL algorithms is that they operate
in a delayed return environment, where it is not obvious to understand
which action leads to which outcome over many time steps. Thus, RL
aims at correlating immediate actions with the delayed returns they
produce. The reinforcement takes place in the sense that RL algorithms
are penalized when making the wrong decisions, and they get rewarded
when making the right one. RL algorithms are expected to increase
performance in more ambiguous, real-life environments (Nguyen et al.,
2017a,b).
2.4. Generative adversarial networks
Generative Adversarial Networks (GANs) are structured, probabil-
istic models for generating data. Being an unsupervised technique,
GANs can be used to generate data similar to the dataset that the GAN
was trained on (Goodfellow et al., 2014; Goodfellow, 2017). Although
relatively new, GANs have already been applied in various ﬁelds, in-
cluding making predictions of compound properties or for molecular
structure generation (Kadurin et al., 2017b; Kadurin et al., 2017a;
Polykovskiy et al., 2018; Zhavoronkov et al., 2018a,b). A GAN consists
of two DNNs called Discriminator and Generator, both diﬀerentiable
functions. The discriminator estimates the probability that a given
sample is coming from the real dataset. It works as a critic and is op-
timized to distinguish the fake samples from the real ones. The gen-
erator outputs synthetic samples using a noise variable as input fol-
lowing a distribution. It is trained to capture the real data distribution
so that it can generate samples with distribution which are as real as
possible. The generator should improve its output until the dis-
criminator is unable to distinguish the generated output from the real
ones.
The two models compete against each other during the training
process. The goal of the generator is to try to trick the discriminator,
while the discriminator attempts to not be cheated. This process is
called a zero-sum game. It happens between the two models and mo-
tivates them to improve their functionalities in order to obtain gener-
ated samples indistinguishable from the real data.
From a conceptual point of view, GANs share similarities with RL.
GANs appear more advantageous in the sense that it is possible to
"backpropagate" the gradient information from the discriminator back
to the generator network. Consequently, the generator knows how to
adapt its parameters in order to produce output data that can fool the
discriminator.
2.5. Transfer learning
Transfer learning (TL) is a ML method where the set of learned
features of a model for a speciﬁc task is reused, or repurposed, as the
starting point for a model on a second task. In practice, TL can be ap-
plied in DL only when the model features learned from the ﬁrst task
remain general. It means that the features learned on the task must also
be suitable for the second task (Torrey and Shavlik, 2010). In practice,
TL is used as an optimization technique that allows saving time or
getting better performance. This can be of great interest given the vast
computational and time resources needed to develop and train DNN
models on problems such as computer vision and natural language
processing tasks, for instance.
2.6. Meta learning
Meta learning aims at applying ML algorithms on metadata ob-
tained from ML experiments to improve the performance of the learning
algorithms themselves. The hypothesis behind meta learning is that by
using diﬀerent kinds of metadata such as properties of the learning
problem, algorithm properties (performance measures), or patterns
obtained from the data, one can learn, select, or combine diﬀerent
learning algorithms to more eﬀectively solve a given learning problem
(Zhou and Wu, 2018; Gupta et al., 2018). This approach could be
especially useful in the context of aging research because the most ef-
fective way to train learning algorithms depends on the type of data
used as well as on the nature of the questions to be answered.
3. Databases for DL for aging research
Various initiatives have been launched to organize and disseminate
the large amount of biological data generated in aging research.
CellAge (http://genomics.senescence.info/cells/) is a manually curated
database of genes associated with cell senescence. The data come from
gene manipulation experiments in diﬀerent human cell types. This
database is hosted within the Human Ageing Genomic Resources, a
collection of databases and tools designed to help researchers study the
genetics of human ageing (Tacutu et al., 2018). It includes various re-
sources such as the LongevityMap (http://genomics.senescence.info/
longevity/)—a repository of genetic association studies of longevity
which aims at aggregating the current knowledge of the genetics of
human longevity (Budovsky et al., 2013). GenAge (http://genomics.
senescence.info/genes/) is a benchmark database of age-related genes.
Geroprotectors (http://geroprotectors.org/) is a curated database of
geroprotectors. It contains more than 250 life-extension experiments in
11 wild-type model organisms, and data about more than 200 chemi-
cals promoting longevity, including compounds approved for human
use that are available. The diﬀerent features of this database are de-
scribed in (Moskalev et al., 2015). The online crowd sourced pathway
annotation database, AgingChart (http://agingchart.org) provides a list
of pathways implicated in aging and longevity (Moskalev et al., 2016).
Another source of information regarding aging research is the Inter-
national Aging Research Portfolio (IARP) (https://agingportfolio.org/).
IARP provides users with access to information about current trends in
aging research, major centers of research, key investigators, and asso-
ciated research programs (Zhavoronkov and Cantor, 2011) (Kolesov
et al., 2014). IARP aims at helping to fund organizations to collaborate,
make decisions, and set future directions for research eﬀorts in aging.
4. Applications of AI in aging research
4.1. Aging biomarker discovery and personalized medicine
Precision medicine is dependent on robust quantitative biomarkers.
Biomarkers of aging are tools able to provide a quantitative foundation
upon which to evaluate the therapeutic eﬃcacy of clinical, health-span-
extending interventions. However, one of the current major impedi-
ments in human aging research is the absence of biomarkers that may
be targeted and measured to track the eﬀectiveness of anti-aging
therapeutic interventions. This might be explained by the fact that
standard biomarkers are usually developed with the purpose of mea-
suring a strictly deﬁned physiological process, and speciﬁc clinical
procedures based on the use of predeﬁned biomarkers. As a result, they
are not necessarily adapted for measuring the eﬀects of a systemic
process such as aging. Currently, many biomarkers of aging monitor not
only one, but a restricted set of physiological functionalities whose
disruptions are known to trigger the onset of speciﬁc diseases and
malfunctions correlated with aging. Although this strategy provides
accurate results and useful information about aging itself, the con-
sidered biomarkers are not always able to represent the health state
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with enough accuracy. Therefore, there is still a need to develop bio-
markers which are objectively quantiﬁable and easily measurable
characteristics of biological aging. The design of such biomarkers, from
an experimental point of view, is a time-consuming and tedious multi-
step process that includes proof of concept, experimental validation and
analytical performance validation. AI technologies oﬀer eﬀective al-
ternatives for the development of aging biomarkers (Fig. 1A and B) and
DL-based aging clocks have already been used to identify quantitative
biomarkers. Diﬀerent conﬁgurations and architectures have been stu-
died. Data types include medical big data obtained through genetics,
genomics (McCue and McCoy, 2017; Leung et al., 2016), biochemistry
(Tetko et al., 2016), proteomics (Issa et al., 2014) and clinical imaging
(Lee et al., 2017a,b). DL-based aging clocks may also diﬀer through
training and validation protocols.
The use and development of such aging clocks must be done with
caution. Indeed, it is important to distinguish the chronological
age—the number of years an individual has been alive—from the bio-
logical age. The biological age, commonly referred to as the physiolo-
gical age or the metabolic age, is the measure of how well the diﬀerent
organs, physiological processes, and regulatory systems of the body
perform and to what extent are being maintained. In theory, monitoring
biological age provides an estimate of the health status of an individual.
Aging clocks estimate biological age from biological data and perform
linear or non-linear regressions for estimating the chronological age of
the individual. Thus, the training protocol of aging clocks aims at
minimizing the diﬀerence, called aging acceleration, between the
physiological age—estimated by the model—and the actual chron-
ological age of the individual. However, it was shown that improving
Fig. 1. Applications of artiﬁcial intelligence to aging research for biomarker development and target identiﬁcation. 1 A. Machine-learned predictors of biological age
at the organismal level and population level. 1B. Machine-learned age predictors at the cell and tissue-level. 1C. Machine-learned predictors of cell type and
diﬀerentiation state.
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tchronological age estimation accuracy through error minimization can
also undermine the biological age acceleration signiﬁcance and reduce
the ability to diﬀerentiate among disease states or mortality risks
(Mamoshina et al., 2018b; Pyrkov et al., 2018). When using ML tools,
such as DL architectures to unravel complex and nonlinear relations
between the features in the data and produce even more accurate
models, it is important to consider that the search for improved accu-
racy does not induce a signiﬁcant loss of biological information.
Nevertheless, more accurate chronological age estimations from bio-
logical samples can ﬁnd applications as described below.
4.1.1. Imaging biomarkers
Magnetic resonance imaging (MRI) is an advanced imaging tech-
nique used for the observation of diﬀerent diseases and parts of the
body. Diﬀerent computational methods can be used for analyzing the
results of MRI. The analysis can be done either for classiﬁcatio-
n—assigning a label to an MRI series (normal/abnormal, level of se-
verity, etc.) or for segmentation—to identify the boundaries of various
tissues. In both cases, the analysis necessitates an extraction of in-
formation from images. The most recent advancements in this ﬁeld
were obtained using convolutional neural networks (CNNs), a type of
neural network specialized for processing image data (Akkus et al.,
2017; Badrinarayanan et al., 2017; Pereira et al., 2016; Liu et al., 2018).
Although MRI images can be used as exclusive inputs for DL models,
other studies have shown the potential to combine them with additional
features. For example, in (van der Burgh et al., 2017), a deep learned
survival predictor for patients suﬀering from amyotrophic lateral
sclerosis—a progressive neuromuscular disease—was assembled using
MRI structural connectivity and brain morphology data in addition to
commonly used clinical characteristics. The model demonstrated 84.4%
accuracy for classifying patients as short, medium, or long-potential
survivor.
Structural MRI data has also been used for age estimation. It serves
as a biomarker for aging in adults, and for patients with conditions such
as Alzheimer’s disease (Cole et al., 2016). Recently, a DNN-based ap-
proach using structural, volumetric features derived from T1-weighted
MRI was shown to outperform RF or ANN for age prediction (Bermudez
et al., 2017). The technique was used on a sample of 3348 subjects aged
from 4 to 26 years. A biomarker called Brain Age Gap (BAG) was cre-
ated. DNNs elicited a BAG of 2.87 years compared to 2.77 years with
ANN, and 2.94 years using RF. Performance of the DNN was improved
by using ensemble methods, with a mean absolute error (MAE) of 2.38
years with a DNN ensemble. These results demonstrate that age can be
accurately predicted with unimodal imaging in a young population
using engineered features instead of raw images. The algorithm de-
veloped in this study could also be used as a biomarker for neurode-
velopment and disease detection that can be easily translatable to the
bedside.
Other types of biomarkers of aging using images as inputs have been
suggested. For instance, in (Bobrov et al., 2018), the authors propose a
novel, non-invasive class of visual photographic biomarkers of aging
using the photographic images of eye corner areas for aging prediction.
The eye corner area of the human face is believed to be the most prone
to aging (Flament et al., 2013). To train and validate the model, a da-
taset of around 8000 high-resolution left and right eye corner photos
with labeled with true, chronological age. The model is based on a
modiﬁed version of Xception (Chollet, 2017), a DNN-based model
where all layers, except the last fully-connected layer are initialized
with pre-trained weights from the ImageNet database. Experiments
showed that the model is able to achieve a mean absolute error of 2.3
years within the age range of 20 to 80 years old. Those results suggest
that high-resolution images of eye corner wrinkles can be utilized to
obtain accurate chronological age estimation. Interestingly, age pre-
dictions for individuals of 70 years old and older were less accurate. A
hypothesis suggested by the authors is that the divergence in human
phenotypes becomes larger as they age. On the other hand, younger
people have relatively the same amount of wrinkles and pigmentation.
This characteristic has also aﬀected the accuracy of age prediction
among very young individuals.
4.1.2. “Omics” biomarkers
A transcriptomic-based age predictor was presented in (Mamoshina
et al., 2018b). To train this model, 545 transcriptomic samples from 12
datasets of human skeletal muscle labeled according to the chron-
ological age, were collected. For this study, several regression models
were built including Elastic Net, SVM, kNN, RF, and Deep Feature Se-
lection (DFS) Model. A linear regression was used as a baseline and its
performance compared to other ML approaches. Although all models
achieved a strong correlation of predicted and chronological age, SVM
and DFS models clearly outperformed the other methods in age pre-
diction, achieving R2 values of 0.83 and 0.83 and mean absolute error
(MAE) values of 7.20 and 6.24 years, respectively. The performance of
models was also evaluated on gene expression samples of the skeletal
muscles from the Gene expression Genotype-Tissue Expression (GTEx)
project.
4.1.3. Multi-modal biomarkers
One of the ﬁrst methods for identifying biomarkers of aging through
population age estimates using DNNs was proposed in (Zhavoronkov
et al., 2016). In this study, an ensemble of 21 DNNs of varying depth
structure was used to predict human chronological age. The features, a
set of 41 biomarkers for each sample, were extracted from tens of
thousands of blood biochemistry samples from patients undergoing
routine physical examinations. Although being highly variable in
nature, the blood biochemistry tests are easy to perform. Furthermore,
they are in clinical use and commonly used by physicians. The best
performing DNN in the ensemble demonstrated a R2 of 0.80 with a
MAE of 6.07 years, while the entire ensemble achieved a R2 of 0.82 and
a MAE of 5.55 years. In order to analyze the importance of the diﬀerent
features used, the permutation feature importance (PFI) method was
utilized. The ﬁve most important biomarkers identiﬁed were; albumin
whose low level is associated with increased risk for heart failure in the
elderly, glucose which is linked to metabolic health; alkaline phos-
phatase whose level in blood increases with age; erythrocytes which are
known to be damaged by oxidative stress; and urea which is known for
increasing oxidative stress. These ﬁve biomarkers monitor the physio-
logical status of renal, liver and metabolic systems, and respiratory
function. The associated features can be used for tracking physiological
processes related to aging.
As explained above, aging acceleration is a biologically relevant
variable associated with the prevalence of major diseases and mortality.
Consequently, aging acceleration can also be connected to overall
health using a scale based on deviation from the patient’s predicted
chronological age. This concept is applied in (Wang et al., 2017) where
a DNN-based predictive model of physiological age was developed with
the Mount Sinai Health System (MSHS) EMR data. Physiological mea-
surements, including vital signs and lab tests from the EMR, were used
as features to train the model. To identify the most relevant features
regarding age predictions, correlation analysis was performed. Among
all the vital signs, pulse pressure and systolic blood pressure show the
strongest positive correlation with chronological age for both genders.
Lab tests positively correlated with age included urea nitrogen, glucose,
hemoglobin A1C, PROTIME/INR; whereas lab tests that most nega-
tively correlated with age are glomerular ﬁltration rate estimate, al-
bumin, total protein, red blood cell count, and hematocrit. Further-
more, correlations between physiological measurements and
chronological age were also investigated using unsupervised hier-
archical clustering on the LOWESS smoothed trends of the most
common physiological measurements across all patients. This approach
allows clustering of diﬀerent physiological measurements with similar
trends. Finally, regression analysis was performed to evaluate how
these variables combine together to predict physiological age. The
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performances of three methods—RF, Elastic Nets, and DNN—were
compared and the DNN showed the best performance. The DL model
was then used for the prediction task. The results show that a combi-
nation of vital signs and lab tests is more predictive of chronological age
than each data type used alone. Patients for which physiological age
was higher than the chronological ones elicit increased prevalence of
hypertension and cardiovascular disorders, increased chronic in-
ﬂammation, possibility of chronic anemia, poor nutritional status, de-
creased kidney function and potential liver damage. On the other hand,
patients predicted younger have, in general, opposite physiological
patterns for many of the physiological measurements, with some ex-
ceptions. The speciﬁc physiological patterns identiﬁed include low risk
for hypertension and hyperlipidemia, healthy kidney and liver func-
tions, healthier nutritional status, and higher risk for venereal diseases.
Taking into account ethnic diﬀerences in health, diet, lifestyle, be-
havior, environmental exposures, and average rate of biological aging,
it was assumed that deep learned biomarkers of aging are population
dependent (Cohen et al., 2016; Zhavoronkov et al., 2016). Using the
results obtained for predicting patient biological age using blood bio-
chemistry, a set of population speciﬁc DL-based predictors of biological
age trained upon blood biochemistry and hematological cell count da-
tasets was presented (Mamoshina et al., 2018a). Samples from patients
belonging to three distinct populations—Canada, South Korea, and
Eastern Europe— were selected. Compared to the ﬁrst study, the
models used less features (21 compared to 41 features) to train three
separate deep networks on three speciﬁc ethnic populations. Models
were trained on 19 blood test features, 15 biochemistry markers, in-
cluding Albumin, Glucose, Hemoglobin, Cholesterol, Sodium, Urea, LDL
Cholesterol, Triglycerides, Hematocrit, HDL Cholesterol, Total Protein,
Calcium, Creatinine, Potassium, and Total Bilirubin, and four are cell
count markers, including Erythrocytes, and Platelet count. Patient sex
and population type were also incorporated in the feature set. As in the
previous work, the age prediction was treated as a regression task. The
model takes a vector of blood test values and returns a single value of
patient age. To evaluate the association of the predicted age accelera-
tion or age slowdown with all-cause mortality, hazard ratios were also
computed. The results showed that the best-performing predictor
achieved an MAE of 5.94 years, having greater predictive accuracy than
the best-performing predictor of the previously reported aging clock
(which achieved an MAE of 6.07 years). Furthermore, as for the pre-
vious studies, deep learned predictors outperformed conventional ML
models. Interestingly, population type appeared as one of the most
important markers for age quantiﬁcation. These results conﬁrm the
hypothesis that ethnically diverse aging clocks are capable of predicting
chronological age, and quantify biological age with greater accuracy
than generic aging clocks.
4.1.4. Epigenetic biomarkers
Epigenetics refers to the mitotically heritable modiﬁcations in gene
expression which do not involve changes within the genetic code.
Epigenetic mechanisms are rather complex, including a combination of
molecular, chemical and environmental factors (constituting the epi-
genome) together with the genome, in establishing the unique func-
tionality of each cell type. DNA methylation is the most studied epi-
genetic mark. DNA methylation is characterized by the addition of a
methyl group to the cytosine in a cytosine-phosphate-guanine dinu-
cleotides or a CpG site. It was demonstrated that DNA methylation
marks elicit an age-associated pattern which has been used earlier to
design several epigenetic clocks of biological age (Hannum et al., 2013;
Horvath, 2013). The assessment of epigenetic DNA methylation age is
based on the association of the methylation level in selected CpG sites
with chronological age, in a population. The methylation level of those
sites can be used to evaluate the chronological age of individuals
(Mitnitski, 2018). Whereas DL techniques were recently applied to
identify epigenetic marks (Kim et al., 2016; Liu et al., 2016), ML
methods are also applied to develop tools using DNA methylation
patterns as a biomarker of aging. For example, in (Torabi Moghadam
et al., 2016) a pipeline of Monte Carlo Feature Selection and rule-base
modeling was developed in order to identify combinations of CpG sites
that classify samples in diﬀerent age intervals based on the DNA me-
thylation levels. In (Levine et al., 2018), an epigenetic biomarker of
aging was developed using data from whole blood. This biomarker was
found to correlate with age in every tissue and cell tested. Furthermore,
it is able to predict a variety of aging outcomes, including all‐cause
mortality, cancers, health span, physical functioning, and Alzheimer's
disease. The combination of large amounts of epigenomics data pro-
duced and stored in the digital space, along with the development of AI
technologies, will lead to the design of more accurate epigenetic clocks
in the near future (Schumacher, 2018).
4.2. Target identiﬁcation
Identifying targets of interest is another critical aspect in the de-
velopment of eﬀective anti-aging treatment. Diﬀerent computational
approaches have been developed, including screening diﬀerences in
pathway activation patterns using pathway perturbation analysis.
Those methods characterize pathways as transcriptomic maps and can
be used to identify pathways eliciting high changes between young and
old individuals. The results of such analysis provide information about
pathways involved in aging (Fig. 2A). Another approach relies on
screening libraries of already known compounds using DNNs for iden-
tifying compounds with potential pro-longevity properties (Fig. 2B)
(Aliper et al., 2016). Features used by aging clocks can also be analyzed
to identify new targets. This approach was followed in (Mamoshina
et al., 2018b) where the list of genes used to predict age based on
transcriptomic proﬁles of skeletal muscles was further analyzed to
identify the genes most important for age prediction. Several methods
were used to evaluate the importance of features (genes) on age pre-
diction. Methods include ranking genes by absolute values of their re-
gression coeﬃcients for an ElasticNet model, applying the RF feature
importance algorithm to extract the Gini importance value of each
gene, and analyzing the relative importance values assigned to genes by
the DFS model. The Borda count algorithm was used to summarize
ranks provided by these diﬀerent methods and obtain ﬁnal importance
values. In addition, the wrapper method, which was applied to identify
the most important blood markers for age prediction (Zhavoronkov
et al., 2016) was also used.
Interestingly, the list of the most important genes selected by the
Borda algorithm contains several genes already known as therapeutic
targets. To provide a more comprehensive overview of how those genes
are related to the aging of skeletal muscles, pathway perturbation
analysis was performed using the iPANDA algorithm (Ozerov et al.,
2016) to compare signatures of young and old muscle tissue. iPANDA
belongs to the fourth generation of data driven pathway analysis
methods (Vanhaelen et al., 2017). Using a simpliﬁed description of the
pathways, these statistical-based methods can handle high dimension-
ality data to analyze changes between two conditions in the expression
of genes belonging to common pathways. As these methods work in
terms of pathway activity levels and not in terms of individual genes,
they reduce the genomic complexity from tens of thousands of features
to measurements on dozens of pathways (Khatri et al., 2012; Li et al.,
2015). The two conditions were deﬁned as follows. The samples from
individuals 16–30 years old were classiﬁed into the “young” group
while individuals over 60 years old were used to assemble the “old”
group. The list of diﬀerentially expressed genes were computed and
their expression proﬁles and a pathway database of 1856 annotated and
manually curated signaling pathway maps were used as an input for the
iPANDA algorithm. The results conﬁrmed the established mechanisms
of human skeletal muscle aging, including dysregulation of cytosolic
Ca2+ homeostasis, PPAR signaling and neurotransmitter recycling
along with IGFR and PI3K-Akt-mTOR signaling.
Drug repurposing is a commonly used alternative approach for
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ﬁnding new targets or indications for already approved drugs.
Computational drug repurposing is a highly active ﬁeld of research
within pharmacology, and many computational approaches are being
developed using various kinds of techniques (Hodos et al., 2016;
Vanhaelen et al., 2016; Alaimo et al., 2016; Vanhaelen, 2019). The
capabilities of DL and AI technologies are also being investigated in this
context. In (Aliper et al., 2016), the authors proposed to use DNN-based
system to classify drugs into therapeutic categories based solely on their
transcriptomic data. Datasets used as inputs include samples exposed to
various drugs selected across A549, MCF-7, and PC-3 cell lines. These
samples were gathered from the LINCS Project and linked to 12 ther-
apeutic use categories derived from the MeSH therapeutic use section.
However, it appeared that training the DNN using the entire dataset of
12,797 genes generated very poor results. In order to address this issue,
feature selection methods were used at the genomic and pathways le-
vels. At the genomic levels, the features were obtained with gene ex-
pression level data for “landmark genes,”—genes that capture ap-
proximately 80% of the information and possess great inferential value.
These features were used to train the DNN classiﬁer. At the pathway
level, the activation scores of 271 signaling pathways were computed
resulting in a ﬁnal dataset containing 308, 454, and 433 drugs for
A549, MCF7, and PC3 cell lines, respectively. Using this dataset, an-
other DNN classiﬁer based only on pathway activation scores for drug
perturbation proﬁles of three cell lines was assembled. Interestingly, it
appeared that this second classiﬁer performed much better, suggesting
that pathway level data is more complementary for DNN and better
suitable for classifying drugs into therapeutic use categories. Inter-
preting their results from a repurposing perspective, the authors argued
that the “misclassiﬁed” samples for a certain drug could be an indica-
tion of its potential for novel use in these exact “incorrectly” assigned
conditions. Misclassiﬁcation, therefore, may lead to unexpected new
discoveries.
Once treatments and drugs have been developed and marketed, it is
important to assess to what extent they can lead to a signiﬁcant im-
provement of health status. Although feedback received from patients
over time can provide meaningful information to improve the drug
development stages or optimize the drug discovery engine (Fig. 2C), it
should be emphasized that the eﬀects of aging take years or decades to
unfold and the experimental observation of the eﬀects of anti-aging
treatments is not necessarily straightforward. For instance, these
Fig. 2. Computational screening for geroprotectors and anti-aging drugs is a multiple process. (A) Pathway and transcriptomic signatures extracted when comparing
young and old individuals help to identify potential candidates and targets. (B) Already existing drugs and compounds can be screened using DNN-based approaches
to identify key properties associated with anti-aging drugs and identify drugs with the desired set of characteristics. (C) Once designed, approved drugs and
compounds reach the market. Feedback from users and patients provide useful information about the reliability of the drug discovery pipeline. Computational
pipelines are ﬂexible and can thus be easily adapted to meet patient expectations.
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diﬃculties are observed when analyzing the eﬀect of the calorie re-
striction (CR) diet. This diet is characterized by a reduction in caloric
intake below usual levels. Observations indicate that CR contributes to
health beneﬁts and extends lifespan. This observation was initially
made in species eliciting a short average lifespan when CR was initiated
early or in mid-life and was sustained for a substantial portion of the
lifespan while maintaining adequate intake of essential nutrients.
However, as emphasized in a recent study where the eﬀects of CR were
analyzed over a period of 2 years (Redman et al., 2018), obtaining si-
milar conclusive results for humans requires performing these experi-
ments over a longer period of time. In addition, other parameters,
which vary over time, such as environmental, economic and social
factors or lifestyle, must be taken into account. One can expect that the
accumulation of health data will allow a more systematic use of com-
putational methods to assess a posteriori the eﬀects of anti-aging drugs
and treatments. For instance, aging clocks can be used to measure how
the aging acceleration in treated patients varies upon treatment (Fig. 3).
Information gathered from individuals can also be used to identify the
main features that characterize the optimal healthy status of an in-
dividual. This information can be applied to understand how anti-aging
drugs counteract lifestyle deleterious eﬀects.
4.3. Small molecules drug discovery
Computational techniques are also developed for the design of drug
compounds and for generating large, virtual chemical libraries which
can be more eﬃciently screened for in silico drug discovery. Drug dis-
covery and development timelines can be further optimized by using DL
and AI technologies to characterize drug candidates according to likely
eﬃcacy and safety, prior to preclinical and clinical trials. The
disruption of the standard discovery pipeline through AI technologies
will be beneﬁcial for the identiﬁcation of new candidates for devel-
oping anti-aging therapies.
In this context, generative models, based on the GAN paradigm for
instance, have great potentials due to their ability to generate virtual
molecules with desired chemical and biological properties. Several of
such models have been proposed for molecular de novo design and
molecular feature extraction. In what follows, we examine the main
models recently released and shortly describe the challenges faced.
Kadurin et al. (2017a) proposed the ﬁrst DL-based generator of
molecules. The core of the architecture is based on an adversarial au-
toencoder (AAE) and aims at generating novel molecular ﬁngerprints
with a deﬁned set of parameters. A molecular ﬁngerprint is a numerical
method to encode the structure of a molecule. The most common type
of ﬁngerprint, called binary ﬁngerprint, is a series of binary digits that
represent the presence or absence of particular substructures in the
molecule. The system takes a vector of binary ﬁngerprints and log
concentration of the molecule as inputs, and outputs a concentration
and a vector consisting of probabilities assigned to each bit of the ﬁn-
gerprint. For training on ﬁngerprint, the log concentration of 6252
compounds proﬁled on the MCF-7 cell line and the corresponding
growth inhibition percentage (GI) data, which indicates the reduction
in the number of tumor cells after drug treatment, were used. To assess
the validity of the predictions, the generated ﬁngerprints were used to
screen several millions of compounds from the PubChem database and
identify the compounds for which anticancer activities are observed.
Other relevant biomedical properties of interest have also been either
tested or demonstrated.
This work was improved in (Kadurin et al., 2017b) where an ad-
vanced AAE model for molecular feature extraction was presented.
Fig. 3. Assessing the eﬃcacy of anti-aging drugs and proposed treatments is critical for advances in aging research. Samples exposed to such treatments or drugs can
be used as inputs for aging clocks. Estimation of age acceleration can be obtained. Comparison with non-exposed samples gives a ﬁrst estimation of the in vivo eﬀects
of these treatments. Another approach relies on the use of AI to extract features characterizing the optimal healthy state reached by most individuals from 25 to 35
years old. Computational analysis can track how these features are aﬀected by various treatments such as the use of geroprotectors. On the other hand, the eﬀects of
various common daily behaviors and lifestyles can also be integrated within these studies.
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Compared to the previous work (Kadurin et al., 2017a), this model,
called druGAN (drug Generative Adversarial Network), also uses ﬁn-
gerprints as a representation of the molecules. In order to measure the
similarity between the generated molecules and the original data, the
authors used the Tanimoto similarity, which is a synonym of Jaccard
similarity in this context. Experiments showed that druGAN elicits
higher adjustability in generating molecular ﬁngerprints, has a better
capacity of processing very large data sets of molecules, and is more
eﬃcient in unsupervised pretraining for regression model. The study
includes a comparison between the druGAN and a variational auto-
encoder (VAE) model. VAE models are another type of commonly used
generative models based on DNN architectures. Interestingly, diﬀerent
tests demonstrated that both AAE and VAE models can perform very
well depending on the kind of task to be solved. Consequently, both
VAE and AAE can be considered as valuable tools that can be used in
drug discovery pipelines on ﬁngerprints and on other representations of
the molecular structure. However, the authors pointed out diﬀerent
limitations of present AAE architectures. For instance, the study used
MACCS molecular ﬁngerprints, which are not ideal representations of
molecular structure. The molecular ﬁngerprint has two disadvantages.
First, one ﬁngerprint can match several molecules, so there is no one-to-
one mapping from a molecule to the ﬁngerprint, and second, the ﬁn-
gerprint representation contains less information about the molecule
topology than the string representation. Those disadvantages are not
shared by other more chemically and biologically relevant representa-
tions of the molecular structures such as the string representation of the
molecule (SMILES), InChI, or molecular graphs. This suggests that using
alternative representations could lead to better performances of gen-
erative adversarial models (Fig. 4A).
Following this conclusion, a VAE model for learning continuous
representation of molecules represented in SMILES format was
introduced by Gomez-Bombarelli et al. (Gómez-Bombarelli et al.,
2018). Models based on Recurrent Neural Networks (RNNs), a type of
architecture more adapted for data of sequential nature such as SMILES,
have also been investigated. For example, in (Bjerrum and Threlfall,
2017), the performances were further improved by using long short-
term memory (LSTM) cells and gated recurrent units (GRU). Archi-
tectures based on the GAN paradigm were also developed. For example,
sequence generation via deep reinforcement learning (DRL) was pro-
posed in (Yu et al., 2017). The architecture, called Sequence Generative
Adversarial Network (SeqGAN), combines GAN with a RL-based gen-
erator. Another extension of SeqGAN called ORGAN (Objective-Re-
inforced Generative Adversarial Network) was proposed in (Guimaraes
et al., 2017). This model adds an “objective-reinforced” reward func-
tion for particular sequences into the SeqGAN reward loss. Further
works based on objective functions for molecular design within the
ORGAN paradigm was done in (Sanchez-Lengeling et al., 2017). The
proposed architecture, ORGANIC (Objective-Reinforced Generative
Adversarial Network for Inverse-design Chemistry), used various cri-
teria as objective ﬁlters to train the ORGAN model. The results showed
the use of diﬀerent objective reward functions makes it possible to bias
the generation process and generates molecules with desired user-spe-
ciﬁed properties.
Following these works, the RANC model for the design of small-
molecules was later presented (Zhavoronkov et al., 2018a). RANC is
based on the GAN and RL paradigms. Moreover, RANC uses a diﬀer-
entiable neural computer (DNC) as a generator. DNC is a category of
neural networks, with increased generation capabilities due to the ad-
dition of an explicit memory bank. This additional module can help to
mitigate common problems found in adversarial settings. RANC was
trained on the SMILES string representation of the molecules and results
showed the generated molecules match the distributions of the lengths
Fig. 4. (A) AI de novo molecular generators oﬀer interesting opportunities to optimize the identiﬁcation and selection of molecules with desired properties. However,
a systematic use of such approaches requires the establishment of standardized procedures and protocols for the training and validation of the models. Furthermore,
systematic studies could be performed to better understand how the model performances depend on the speciﬁc architecture, loss functions, and combination of
ﬁlters used. (B) AI-molecular generators are best used in combination with aging clocks. Targets identiﬁed from aging signatures and features used by aging clocks
are used to deﬁne appropriate properties of molecules generated by AI generators. As for any computational methods, predictions obtained from AI-based generators
must go through various phases of testing. Feedbacks obtained from these critical steps can help improve the global pipeline.
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and the key molecular descriptors of the training molecules. Further-
more, comparisons with ORGANIC showed that RANC performed better
in terms of number of unique structures, Muegge criteria, QED scores
and number of generated molecules passing the medicinal chemistry
ﬁlters (MCFs).
Another variant of molecular generator called Adversarial
Threshold Neural Computer (ATNC) was also designed (Zhavoronkov
et al., 2018b). Like the RANC and ORGANIC models, ATNC is based on
the GAN and RL paradigms and, like RANC, it also uses DNC as gen-
erator. However, ATNC includes a supplementary computational unit,
called adversarial threshold (AT). The AT unit acts as a ﬁlter between
the agent (generator) and the environment (discriminator and objective
reward functions). In order to generate more diverse molecules, a new
objective reward function named Internal Diversity Clustering (IDC)
was introduced. The performances were compared with ORGANIC and
both models were trained on the SMILES string representation of the
molecules. Four objective functions, the internal similarity, the Muegge
druglikeness ﬁlter, presence or absence of sp3-rich fragments, and the
IDC were used. The distributions of four molecular de-
scriptors—number of atoms, molecular weight, logP, and tpsa—were
analyzed and ﬁve supplementary chemical statistical features were also
computed (internal diversity, number of unique heterocycles, number
of clusters, number of singletons, and number of compounds that have
not been passed through medicinal chemistry ﬁlters). The analysis of
these molecular descriptors and chemical statistical features demon-
strated that the molecules generated by ATNC elicited better drugli-
keness properties. One of the limitations of the ATNC emphasized by
the authors concerns the architecture itself. It was suggested that re-
placing the GAN part by an AAE can provide the model with a me-
chanism to control the percentage of correctly reconstructed molecules.
Other main limitations are related to the method used for representing
the molecules. ATNC, RANC and ORGANIC are SMILES-based models
and cannot properly employ fragment-based objective reward func-
tions. This is due to the fact that SMILES string of a fragment cannot be
found in a SMILES string of a molecule because of the SMILES format
notation. The authors suggested that using other molecule representa-
tion, for example graph representation of molecules, where each mo-
lecule will be represented in a unique way, could overcome this issue.
Finally, they suggested that using modern, multi-objective RL techni-
ques could allow the environment to optimize the scoring of the mo-
lecules by using several objective rewards simultaneously (Fig. 4A).
The examples discussed in this section illustrate this growing ﬁeld of
research still lacks a uniﬁed set of benchmarks which could be used to
provide a framework to evaluate and compare diﬀerent generative
models. Furthermore, it is necessary to formulate best practices for this
emerging industry of ‘AI molecule generators’ at diﬀerent levels, in-
cluding how much training data is required, for how long the model
should be trained, and what kind of metrics and loss functions are the
most appropriate for monitoring the performance and assessing the
validity of the outputs of these models. For example, replacing hand-
crafted rules commonly used in the context of de novo drug design with
rules learned from data. DiversityNet is a promising initiative to address
this issue. DiversityNet is a data science collaborative challenge which
asked participants to collaborate to design the most appropriate set of
tasks, metrics, and select suitable datasets to evaluate generative mo-
lecule generators. AI-molecular generators have already been success-
fully integrated in extended pipelines where their prediction power and
accuracy are improved by using biologically relevant features selected
through the use of aging clocks and other dimensionality reduction
techniques (Fig. 4B).
4.4. Regenerative medicine
The ﬁeld of regenerative medicine aims to provide patients with
improved treatment and faster recovery through, for example, the use
of induced pluripotent stem Cells (iPSCs) (Takahashi and Yamanaka,
2006; Takahashi et al., 2007) which can diﬀerentiate into diﬀerent cell
lineages and ultimately, to any kinds of cell types (Scudellari, 2016;
Yamanaka, 2012). Therefore, one could control iPSC diﬀerentiation to
treat various diseases (Jiang et al., 2014). For example, by creating beta
islet cells to treat diabetes or neurons to treat neurological diseases.
These techniques could also be used to grow tissues and organs and
transplant them into the body, eliminating potential organ transplant
rejection. If applied at a larger scale, this could help to address the
shortage of organs available for transplants.
However, the use of iPSC potentials requires fully controlling the
diﬀerentiation process itself. In past decades, much progress has been
made to understand the complex dynamics taking place during the stem
cell fate decision at the genetic and epigenetic levels. At the genomic
level, pluripotency maintenance is regulated by transcription factors
(Thomson et al., 2011; Walker et al., 2007; Walker and Stanford, 2009;
Tantin, 2013) which act as master regulators of gene regulatory net-
works (GRNs) (Iglesias-Bartolome and Gutkind, 2011; Ng and Surani,
2011; Dalton, 2013). From a dynamical point of view, GRNs are orga-
nized following various dynamical motifs which act together and con-
tribute to improving the adaptation abilities and robustness of the
system (Yeo and Ng, 2013; Saint-André et al., 2016). Transcription
factors have been shown to continually attempt to specify diﬀerentia-
tion to their own lineage. Consequently, direct external interventions,
through activation or inhibition of one or several signaling pathways,
are necessary to reinforce the pluripotency state or to control the dif-
ferentiation to a speciﬁc lineage (Silva and Smith, 2008; Nowick and
Stubbs, 2010; Loh and Lim, 2011). From this point of view, the plur-
ipotency state could be considered a metastable state whose main-
tenance depends on the properties of the external environment of the
cell. These discoveries explain why diﬀerentiating iPSCs into speciﬁc
cell types can only be achieved by following a rather complex diﬀer-
entiation protocol, usually speciﬁc to each kind of cell (Malik and Rao,
2013).
Although signiﬁcant eﬀorts and progresses have been accomplished
to establish standardized sets of diﬀerentiation protocols for various
cell types (Si-Tayeb et al., 2010; Takeda et al., 2017; Dai et al., 2015;
Daniel et al., 2016), large scale applications are still diﬃcult. Within
this context, computational methods could be used to design AI auto-
mated systems to create and adjust custom protocols to optimize the
success of stem cells diﬀerentiation processes. The opportunities oﬀered
by AI techniques in the development of predictive models for perso-
nalized treatments with engineered stem cells, immune cells, and re-
generated tissues in humans were recently reviewed in (Sniecinski and
Seghatchian, 2018). For instance, AI can be used to identify the state of
development of embryonic cells (Fig. 1C). An example of this kind of
application was recently published in (West et al., 2018). In this study,
a DNN ensemble was trained on transcriptomic data of 12,404 healthy,
untreated tissue samples from Aﬀymetrix (4822 samples) and Illumina
(7582 samples) microarray platforms to be able to classify samples
according to ﬁve categories: embryonic stem cells (ESCs), induced
pluripotent stem cells (iPSCs), embryonic progenitor cells (EPCs), adult
stem cells (ASCs) and adult cells (ACs). The DNN outperformed tradi-
tional ML methods (kNN, SVM, GBM) and achieved a mean 0.99 F1
score—the probability that the guesses are correct—on the Aﬀymetrix
microarray training dataset, and 0.75 F1 on the external validation
dataset. Interestingly, prediction performances of the DNN were im-
proved with dimensionality reduction using the pathway level analysis
approach iPANDA. Further feature importance analysis identiﬁed re-
pression of COX7A1 as a novel marker associated with the mammalian
embryonic-fetal transition (EFT). The computational methods devel-
oped in this work have been made available through an online platform
called embryonic.ai (http://embryonic.ai). The AI-based platform was
developed by Insilico Medicine Inc. in collaboration with the company
Biotime Inc., (http://www.biotimeinc.com/). It gives access to the ﬁrst
deep learned transcriptome-based classiﬁer designed to compute the
embryonic score of a sample, an integrative metric of cell development
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stage. Embryonic AI is an ensemble of DNNs trained and validated on
transcriptomics data representative of healthy ESC, iPSC, EPC, ASC and
AC types. Using data provided by the user, the system will output an
embryonic score.
Another example of application of AI technology is the recent in-
troduction of an online catalog of 3D stem cell images produced using
DL analyses and cell lines altered with the gene-editing tool CRISPR
(Maxmen, 2017). This tool, called Allen Cell Explorer (https://www.
allencell.org/), will be used in the near future by scientists to better
understand iPSC structures and their relationships to functions, and
ultimately to diseases like cancer.
At a larger scale, AI can also oﬀer practical solutions to other types
of challenges faced in regenerative techniques with the prediction of
tissue engineering results with ANN (Xu et al., 2005; Shaikhina et al.,
2015) or with the development of computational model-based neural
networks for more elaborated tissue engineering applications. One can
expect the current trend toward AI-guided regenerative medicine will
bring impactful beneﬁts in the near future.
Applying such regenerative technologies to design anti-aging drugs
or treatments targeting age related diseases is an appealing perspective.
Several companies focus on developing such treatments but most of the
clinical applications will require years of development and clinical
trials before potential FDA approval. Nevertheless, several near-term
applications are already undergoing clinical trials. This is the case for a
regenerative product for age-related macular degeneration which is
developed by AgeX Therapeutics (http://www.agexinc.com/), a sub-
sidiary of BioTime, Inc. AgeX Therapeutics is also developing plur-
ipotent stem cell-derived therapies for manufacturing brown fat cells.
These cells contribute to the regulation of metabolism as they burn
calories rather than store them. The amount of brown fat cells within
the body decreases with age and restoring them might help maintain
the metabolic balance at the same level as younger individuals.
4.5. Gene therapy
Gene therapy is an experimental technique that uses genes to treat
or prevent diseases, including inherited disorders, some types of cancer,
and certain viral infections. In practice, this technique is designed to
introduce genetic material into cells to compensate for abnormal genes
or to make a beneﬁcial protein. Although promising, gene therapy is
currently being tested only for diseases that have no other cures
(Soleimani et al., 2015). However, in recent years gene therapy has
gained more attention due to several successes. The FDA has recently
approved the ﬁrst gene therapies for treating forms of leukemia, lym-
phoma and retinal dystrophy—an inherited disease. Although these
initial successes did not beneﬁt from the emergence of AI techniques,
the rapidly growing amount of genomic data available has, like in other
ﬁelds of life science, triggered the interest applying AI for improving
gene therapies and as a consequence, the potential of personalized
medicine as both of them rely on matching the appropriate drug with
the right patient population. A task for which AI technologies are per-
fectly adapted (Fig. 5). More speciﬁcally, one sees AI as a key ingredient
to improve the precision of the gene editing process. Although the de-
velopment of gene editing has provided new opportunities for exploring
personalized cures and treatments by providing scientists with the
ability to alter patient DNA, the ability to perform gene editing accu-
rately is still challenging. Several companies have developed AI-based
platforms to answer the needs of this speciﬁc sector. For example,
ATUM (https://www.atum.bio/), a California-based bioengineering
service organization, and the largest US-based provider of synthetic
genes, is applying AI to gene synthesis and has developed a technology
called Leap-In transposase which enables any recombinant DNA se-
quence to behave as a transposon. Synpromics (http://www.
synpromics.com/), an Edinburgh-based company, uses AI to identify
patterns between genomic sequences and their involvements in cell
type-speciﬁc regulation of gene expression. Elevation, the project
developed by Microsoft, uses genomic data and AI to predict the op-
timal position to edit a strand of DNA to alleviate side eﬀects and speed
up the editing process (Listgarten et al., 2018).
Gene therapies also oﬀer tremendous opportunities for designing
eﬃcient anti-aging treatments. It is known that mitochondrial oxidative
stress may contribute to human aging. For example, increased expres-
sion of catalase in the mitochondria results in much more potent pro-
tection against oxidative stress (Bai et al., 1999; Arita et al., 2006). To
take advantage of this discovery, it has been suggested that an adeno-
associated virus vector expressing the mitochondria-targeted catalase
gene could be used as a gene therapy to prevent aging-related pa-
thology (Li and Duan, 2013). Telomerase gene therapy is another
possible application. This approach is based on the observation that
telomere shortening is linked with aging and disease and that the ge-
netic manipulation of lengthening telomeres through increased telo-
merase expression may result in increased longevity. Telomerase gene
therapy is a possible therapeutic intervention against aging and
age‐related diseases (Boccardi and Herbig, 2012; Bär et al., 2016;
Muñoz-Lorente et al., 2018). One can expect that the use of AI tech-
nologies to optimize the design of gene therapies will greatly help the
future development of anti-aging treatments.
4.6. Immuno oncology and immunosenescence
Cancer is currently one of the main causes of death. This is due to an
aging population but also possibly related to unhealthy food habits,
changing lifestyle, and increasing consumption of tobacco-related pro-
ducts. According to the National Cancer Institute, around 1.6 million
new cases of cancer were diagnosed in the USA in 2016. As these
numbers are expected to grow in the future, there is an increasing and
pressing demand for identifying new oncology drugs that can be used as
a part of anti-cancer treatments. Normally, the immune system is able
to recognize tumor cells and distinguish them from their normal
counterparts. However, in cancer patients, tumor cells escape from
immune system surveillance by dodging immune checkpoints (in-
hibitory pathways to inactivate T-cells). Oncology drugs, also called
anti-cancer drugs or anti-neoplastic drugs, are agents that can be used
alone or in combination to control or destroy neoplastic cells. These
agents can be either systemic or targeted. In systemic, the drug spreads
throughout the body, whereas in targeted, the drug or substance
identiﬁes the speciﬁc location causing less harm to the growth of
neighboring healthy cells. There are several types of Cancer
Immunotherapies using either Immune Checkpoint Modulators,
Immune System Modulators or Therapeutic antibodies, Immune Cell
Therapy, or Cancer Vaccines, usually made from a patient’s own tumor
cells or from substances produced by tumor cells.
A speciﬁc challenge when treating cancer comes from the fact that
each cancer and every cancer patient are diﬀerent and tumor cells
within a speciﬁc tumor site can vary in diversity. For that reason, a
strategy pursued in oncology research is to identify small subsets of
cancer patients that can beneﬁt from a speciﬁc treatment. However, this
targeted approach has encountered limited success until recently, be-
cause although researchers and doctors had access to large sets of data
from imaging, genomics, co-morbidities and previous treatments, they
did not have the adapted methods to make an eﬃcient use of them.
With its ability to learn, predict, and advice based on vast amounts
of data, AI technology can identify patterns that can be used to predict
the prognosis of patients and advise medical practitioners with diﬀerent
options available ranging from available personalized medicine to
clinical trials with experimental therapies (Fig. 5). For example, con-
volutional neural networks (CNNs) were trained to classify cancer pa-
tients using immunohistochemistry of tumor tissues (Vandenberghe
et al., 2017). A ML-based tumor classiﬁer was presented in (Capper
et al., 2018) and works using ML methods speciﬁcally for breast cancer
pattern classiﬁcation and forecast modeling. These methods were also
reviewed in (Yue et al., 2018). Applications of standard ML-techniques
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for cancer diagnosis have been covered in (Kourou et al., 2015) and DL-
based cancer diagnosis approaches were recently reviewed in (Hu et al.,
2018). As in the case of regenerative medicine, applying AI technology
as a diagnostic tool in oncology (detection of cancer) can signiﬁcantly
reduce the error rate of diagnosis and also contribute to reducing time-
consuming activities. There are many initiatives to support the appli-
cation of AI within oncology. For example, the open research initiative
called EPIDEMIUM aims to bring together multiple players and apply AI
to the research of new cancer therapies. Many companies are working
to develop AI-based platforms to address challenges faced in oncology
and cancer research. For instance, AI is used by the company Sophia
Genetics to pinpoint the gene mutations behind cancer to assist doctors
in the prescription of the best treatment. The company Freenome de-
veloped an AI genomics platform to predict patients’ responses to im-
muno-oncology therapies by observing changes in biomarkers circu-
lating in the bloodstream. In addition to being used to stratify patients,
AI can also be applied to identify synergistic combinations of cancer
targets in order to develop drugs against those targets; this strategy is
followed by Sanoﬁ and GSK which have partnered with Exscientia.
These eﬀorts, although in their infancy, begin to generate results with
the case of the company BenevolentAI which, in partnership with
Janssen, has shown concrete results, leading to a drug candidate now
moving to a Phase II trial.
In non-cancerous cells, the immune system also undergoes altera-
tions with age. The most important alterations occur in the adaptive
immune system and involve T cells. Many of these alterations are as-
sumed to decrease capacity of the immune system to combat the
emerging or progressing tumor (Pawelec et al., 2010; Fulop et al., 2010;
Pawelec, 2017). The declining function of the immune system is known
as immunosenescence and leads to a higher incidence of infection,
cancer, and autoimmune disease related mortalities in the elderly po-
pulation (Pawelec, 2018). For these reasons, various strategies have
been suggested to combat immunosenescence, including cellular and
genetic therapies (Xu and Larbi, 2017). Immunosenescence involves a
shift in function of both adaptive and innate immune cells, leading to
reduced capacity to recognize new antigens and widespread chronic
inﬂammation (Stahl and Brown, 2015; Ventura et al., 2017). This state
can be assessed by measures of diﬀerent immune biomarkers that are
diﬀerent in younger and older individuals and are associated with a
detrimental clinical outcome. Many other biomarkers were assessed in
studies of younger and older adults. Well established markers of im-
munosenescence include CD45RO, CD45RA (Neuber et al., 2003), CD27
(Bulati et al., 2011; Xu and Larbi, 2017) CD57 (Xu and Larbi, 2017) and
CD28 whose downregulation occurs in response to chronic immune
stimulation in older individuals (Kennedy et al., 2016; Tu and Rao,
2016). CD31 is known as a good marker of CD41+T cells (Larbi and
Fulop, 2014; Douaisi et al., 2017) whereas CD79 A is a highly reliable
marker for B-cells. Downregulation of several genes has been associated
with a decrease in immune functions. For example, KLF4 whose ex-
pression may wane with age is known to control immune function
(Kennedy et al., 2016). TSPAN33 also wanes with age and plays a role
in red blood cell diﬀerentiation (Kennedy et al., 2016). Interleukin-7
(IL-7) plays a central, critical role in the homeostasis of the immune
system (Nguyen et al., 2017a,b). Immunosenescence is also correlated
with a lower expression level of IL-2 as highly diﬀerentiated T cells
accumulate with age and are unable to produce IL-2 (Henson and
Akbar, 2009). Other examples of genes whose expression is positively
or negatively correlated with the onset of immunosenescence are de-
scribed elsewhere (Bellavista and Franceschi, 2009; Opal et al., 2005;
Xu and Larbi, 2017; Rosenstiel et al., 2008). There have been several
studies where computational methods were applied to investigate the
mechanisms behind the onset of immunosenescence, especially its in-
terconnection with inﬂammation (Morrisette-Thomas et al., 2014;
Bektas et al., 2017). However, in the near future, our understanding of
immunosenescence and its interconnection with other processes could
take advantage of similar methodologies rather than the ones used for
predicting biological ages. AI technology could identify key regulators
involved in the onset of immunosenescence and reveal the complexity
of the interplay with other key biological processes. These regulators
could, in turn, become targets for developing appropriate treatment.
5. AI for cross-species aging research
Demographic data, or life tables, such as the ones from the Human
Mortality Database (http://www.mortality.org) provide information to
analyze demographic trends including mortality and fertility rates.
Using life tables, one can extract survival curves showing the propor-
tion of individuals surviving to each age for a given species. The ana-
lysis of these curves demonstrate that they elicit speciﬁc topological
features which provide information about the speciﬁc aging patterns of
each species (Jones et al., 2014). As described in (Demetrius, 1978),
survival curves can be broadly classiﬁed into three types. The Type-I
survival curves change at early and middle ages and then decline at late
ages, as seen for humans. The Type-II curves almost linearly decrease
with age, as seen for short lived birds. Type-III curves quickly decrease
at early ages, as seen for most plants. Nevertheless, major, non-trivial
topological features of these curves are still poorly understood and a
current challenge in fundamental aging research is to ﬁnd how aging
Fig. 5. AI can be used in diﬀerent ways for designing personalized treatments. AI platforms can be used as a diagnostic tool to reduce error rate. It is also useful to
stratify patients according to their speciﬁc health condition. By combining more accurate diagnostics and a better knowledge of the health conditions of the patients,
AI platforms can be applied to design more eﬀective treatments.
A. Zhavoronkov et al. Ageing Research Reviews 49 (2019) 49–66
60
patterns and mortality curves are shaped. To that end, it is necessary to
identify the mechanisms responsible for the observed shapes. Currently,
there are several causal and relatively complex mechanistic models
which have been built to describe some of these topological features
(National Research Council (US) Committee on Population, 2012). Al-
though, some of the models successfully predict several curves for
species, they do not provide a complete framework for explaining the
diversity of aging patterns observed through the tree of life (Liu, 2015;
Dolejs, 1997; Kogan et al., 2015). The diﬃculty comes from the fact
that the mortality curves are the result of complex relationships be-
tween living styles, eﬀects of natural selection, environmental condi-
tions, and ﬁne-tuning of cellular mechanisms. Many of these parameters
are speciﬁc to each species (Vanhaelen, 2015; Vanhaelen, 2018). Al-
though these models can include variables such as resource availability,
reproduction rate, and the eﬀects of competition between species,
considering the eﬀects of ﬁne-tuning of cellular mechanisms is still
challenging. This requires having a detailed description of these me-
chanisms, that is, a description of how aging occurs and propagates
with the living system. It is well known that there are many mechan-
isms contributing to aging, including inﬂammation, apoptosis, oxida-
tive stress, accumulation of DNA damage, cell cycle deregulation, mi-
tochondrial dysfunction, and telomere shortening, to name a few. A
classical modeling approach would be to elaborate models combining
the eﬀects of accumulation of mutations, senescence, eﬀects of natural
selection and any other parameter and process supposed to intervene in
the onset and propagation of aging. Such a task presents tremendous
technical challenges (Tarkhov et al., 2017) that is made even more
complex by the fact that one can reasonably assume many of the me-
chanisms or biological parameters which should be included in such
models are still either poorly understood or even completely unknown.
Another approach (Fig. 6) would take advantage of the ability of AI
techniques to design speciﬁc algorithms whose goal should be to sys-
tematically analyze the demographic data available for various species
in order to identify and extract the major features behind the shape of
survival curves. In addition, AI platforms could be designed to perform
cross-species analysis of such data. This could allow the examination of
common and distinct features of the aging process through diﬀerent
species. The results of such investigations could lead to the identiﬁca-
tion of generalized aging biomarkers. This approach could also be used
to analyze how evolution has shaped diﬀerent species’ aging patterns.
6. Generative adversarial networks (GANs) for generation of
synthetic data and target identiﬁcation
As previously described, GANs represent a powerful new tool for the
generation of synthetic data. In situations where patient-speciﬁc data-
sets are scarce, it is possible to use GANs to signiﬁcantly augment the
original data set by producing new data across the broad spectrum of
ages. It is also possible to simulate patient cases that did not exist in
nature by generating patients older than the current record of 122.5
years. This powerful technique can also be used to infer causality and
identify actionable biological processes or targets. By generating the
“older” or “younger” representation of the individual patient or patient
subpopulations, it is possible to identify the most important features
responsible for this change and explore the dependencies between these
features. The illustration in Fig. 7 (A) demonstrates this concept using
photographic data. It is clear from the photographs that the generated
130 year old subject looks older than the original or synthetic 20-year
old subject. The applications of GANs to the generation of shorter and
longer-lived subjects depicted in Fig. 7 (B) may help identify the drivers
of the aging process as well as the protective mechanisms.
7. Aging research for advancing artiﬁcial intelligence
While advances in AI are already making substantial contributions
to research in aging, the computational solutions speciﬁcally developed
for aging research could substantially advance research in AI. For op-
timal use in aging research, AI should not only provide correct pre-
dictions, but also give information about the features used to obtain the
predictions. The results provided should be interpretable in terms of
initial inputs, which can be of highly diverse origins. There have al-
ready been several breakthroughs in making AI systems more inter-
pretable, contributing to the development of new memory systems
capable of capturing multi-modal continuous data and eﬃciently for-
getting unnecessary information.
Improving the interpretability of AI-based algorithms can be done
using two diﬀerent complementary approaches. First, the complex data
collated in many biological databases are well suited to DL but also
Fig. 6. AI algorithms are capable of handling large amounts of data and identify relevant patterns without prior information about the related phenomena. For this
reason, AI algorithms are adapted to analyze the complexity of demographic data. Analysis can include the extraction of the most important features used to
reproduce the topology of species. Speciﬁc curves can give an overview of the most important mechanisms involved. Cross species analysis could provide ex-
planations about the origins of the huge diversity observed through the tree of life. The information gathered could be used to design generalized aging biomarkers,
identify common features of aging across species, and improve the understanding of how evolution shaped aging across species.
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contain challenging features, including high dimensionality, noise, and
multiple, often incompatible, platforms. Consequently, while AI archi-
tectures are able to extract features from the data automatically and
usually outperform other ML approaches in feature extraction tasks, it is
recommended to select a set of relevant features before training DL
models. Feature selection and extraction can involve dimensionality
reduction. Generic methods such as principal component analysis or
clustering methods can be applied. However, other feature extraction
methods preserving the biological function can also be used. In prac-
tice, the appropriate reduction and feature extraction methods heavily
depend on the context of the study. For instance, when dealing with
transcriptomic data, dimensionality reduction should be applied prior
to training DNNs because the dataset contains a number of samples
much smaller than the number of genes. Supervised, knowledge-based
approaches such as the gene aggregation method, like pathway ana-
lysis, are the most suitable tool to that end. The list of the most relevant
perturbed pathways is then taken as the new list of features. The
strategy is to ensure that the features are relevant with respect to the
biological problem under study. Besides the appropriate selection of
feature prior to the training of the model, the predictions obtained from
AI algorithms can be better interpreted by using methods such as the
permutation feature importance (PFI) technique (Altmann et al., 2010)
which allows evaluating the relative importance of features to DNN
prediction accuracy. Speciﬁc type of architectures, like DFS models (Li
et al., 2016), automatically implement similar procedures. These
ranked lists of features can be used as a starting point to investigate the
mechanisms behind the observed biological behavior and to put the
prediction of the algorithm in context.
8. Artiﬁcial general intelligence (AGI) for aging research
While there are multiple eﬀorts to develop artiﬁcial general in-
telligence (AGI), also referred to as the sentient AI, and even transfer of
the human memory and capabilities into computers, there is no proof of
concept demonstrating the feasibility of any of these approaches
(Wallach et al., 2010; Deca and Koene, 2014). However, there is sub-
stantial debate on AI safety and ethics. Regardless of the winning ap-
proach to AGI and the probability of AGI emerging in the near future, it
may be important to develop a values-based rules book to train AGI to
maximize the number of quality-adjusted life years (QALY) for ev-
eryone in the population. Maximizing global longevity and human
health span should be taught as the ultimate form of altruism to AGI.
9. Conclusion
The revolution in deep learning which started with deep neural
networks outperforming humans in ImageNet competition (He et al.,
2015) and RL in video games (Mnih et al., 2015) is rapidly propagating
into aging research. These eﬀorts are driven by academia and industry
with the inﬂux of government funding and venture capital. Aging is a
universal feature possessed by most living organisms, and therefore,
most of the advances in deep learning in the context of aging research
are in the ﬁeld of biomarker development. Many age predictors are
commonly referred to as “aging clocks” developed for multiple data
types ranging from basic clinical blood tests, photos, videos, voice,
retinal scans, and medical imaging to microbiome data. These feature
selections, feature importance analysis, multimodal data analysis eﬀorts
and causal model development eﬀorts not only help estimate the bio-
logical relevance of these data types but also help advance research in
Fig. 7. GANs are well known for their abilities to generate models from data. These features have been largely used for image generation. Combining this ability with
the capabilities of GAN to handle large sets of data to capture complex features across individuals at diﬀerent age, one can build GAN-based architecture to generate
synthetic health data and pictures of individuals at any age using the health data at a known given age.
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AI by making the DNNs more interpretable.
The applications of AI presented in this work illustrate that AI
technologies are rapidly emerging and are starting to deliver promising
results in diﬀerent ﬁelds of aging and longevity research (Fig. 8). One
can expect that multidisciplinary approaches combining the ability of
modern AI to generalize, learn strategy, generate new models, objects
and data from learned features with accurate methods for feature ex-
traction and causality analysis will lead to new applications in every
area of preventative, regenerative and restorative medicine. AI pro-
gressively moves from the status of an overhyped technology with only
a few proof-of-concept examples to a massively-adopted and accepted
trend in healthcare. An example of this trend happened in early 2017
when the ﬁrst DNN based platform, Arterys Cardio DL, was oﬃcially
approved by the FDA. This platform is now widely used in the clinic.
Systems like Young.AI (http://young.ai) and aging.ai (http://aging.ai)
which estimate the predicted biological age of a person using multiple
data types may provide valuable insights into the person’s health status
and evolve into disease-speciﬁc applications. Multi-modal integration
of the multiple aging clocks using modern AI will lead to a more holistic
approach to the understanding of biology and provide a uniﬁed theory
of aging and repair.
Encouraging progress can be seen from regulatory institutions.
Many regulatory authorities have initiated the development of a reg-
ulatory framework to promote innovation and support the use of AI
technologies in healthcare. The ﬁrst cloud-based DNN has recently been
approved by the FDA under the category of medical devices. In the EU,
a legislative proposal for regulations related to software for medical
devices for prediction and prognosis is currently under review.
In addition to the many technical challenges still faced by AI tech-
nologies, another major concern in the application of AI technologies
within healthcare is related to the acquisition, generation, and use of
health data. Many people consider their health information private and
agree that it should be protected, accordingly. Patients usually want to
know how their information is being handled. The fact that the transfer
of medical records from paper to electronic formats could increase the
chances of individuals accessing, using, or disclosing sensitive personal
health data, has triggered a lot of privacy concerns.
To address these concerns, regulatory eﬀorts are underway to en-
sure proper ﬂow and use of healthcare records. The most recent de-
velopment is the General Data Protection Regulation (GDPR) enforce-
ment established in Europe which has strong implications for the
development of AI-based platforms. Although these regulations are
welcome and necessary to avoid abusive practices, regulatory institu-
tions should ensure that they do not become barriers to meaningful
technological development. The ability of AI to make accurate predic-
tions is heavily dependent on data availability. Access and regulation
should take into account that collaboration between healthcare and AI-
based companies is necessary to establish an eﬃcient pipeline for data
acquisition.
The population speciﬁcity of the many aging biomarkers demon-
strates the need for international collaborations and consortiums fo-
cused on data economics, generation, and exchange, model exchange
and validation as well as meta-analysis, clinical trials and educational
programs.
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